KRSA (KRSA)

NASDAQ: KRSA · USD

$30.2

+0.10 (+0.3%)· Recorded snapshot

Market cap	1.4B
Net income (ttm)	-49.1M
EPS (ttm)	-$13.4
Shares out	45.5M
Volume	107,498
Beta	1.73

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -49.1M
EPS (ttm): -$13.4
Market cap: 1.4B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROEn/a

P25 -113.8P50 -46.5P75 -0.9

ROICn/a

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All KRSA indicators

Market & fundamental data

Available fields

156

Groups with data

Currency

USD

Showing 156 of 156 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001755237
Country	United States
Country code	US
CUSIP number	23255M303
Earnings date	2026-11-11
Earnings time	amc
Employees	19
Employees change	0
Employees growth	0%
Enterprise value	$1.2B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-03-31
First seen	2026-10-09
Fiscal year end	December
Founded	2024
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US23255M3034
Last refreshed	2026-10-28
Last stock split date	2026-09-09
Last stock split type	Reverse
Market cap	$1.4B
Market cap category	Small-Cap
Next earnings date	2026-11-11
Price	$30.17
Price currency	USD
Sector	Healthcare
Stock price date	2026-10-28
Symbol	KRSA
U.S. state	Massachusetts
Website	https://korsana.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-44.32%
FCF / EV yield	-3.4%
FCF yield	-3.07%
P/B ratio	10.64x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-2.6M
ROCE	-39.95%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	6
Net income growth years	0
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-165,000
EBIT	$-51.9M
EPS	$-13.37
FCF per share	$-0.92
Financing cash flow	$166.2M
Free cash flow	$-42M
Free cash flow minus SBC	$-44.3M
Investing cash flow	$-165,000
Net cash flow	$124.2M
Net income	$-49.1M
Operating cash flow minus SBC	$-44.1M
Operating income	$-51.9M
Stock-based compensation	$2.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$-7.84
Debt / equity	0.01
Long-term assets	$2.6M
Long-term liabilities	$1.4M
Net cash (debt)	$133.1M
Net cash / market cap	9.73%
Net debt / equity	-1.04
Piotroski F-Score	1
Property, plant and equipment	$1.3M
Shareholders' equity	$128.5M
Tangible book value	$-47M
Tangible book value per share	$-7.84
Total assets	$137.7M
Total cash	$134.2M
Total debt	$1.1M
Total liabilities	$9.2M
WACC	13.73%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$135.1M
Current liabilities	$7.8M
Current ratio	17.4
Net working capital	$-6.7M
Quick ratio	17.28
Working capital	$127.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$25.79
1D price change	0.33%
1M price change	-1.5%
1M total return	-1.5%
1W price change	-1.6%
1W total return	-1.6%
1Y price change	107.72%
1Y return CAGR	107.83%
1Y total return	107.72%
20-day SMA	$32.09
200-day SMA	$21.76
3M price change	24.63%
3M total return	24.63%
3Y price change	45.41%
3Y return CAGR	13.29%
3Y total return	45.41%
50-day SMA	$31.04
50-day SMA vs 200-day SMA	50over200
52-week high	$59.36
52-week high date	2026-04-01
52-week low	$7.19
52-week low date	2026-02-09
5Y price change	-91.64%
5Y return CAGR	-39.13%
5Y total return	-91.64%
6M price change	48.88%
6M total return	48.88%
All-time high	$3,199.00
All-time high date	2019-04-01
All-time low	$7.19
All-time low date	2026-02-09
Average true range (ATR)	$2.86
Average volume	138.5K
Beta (1Y)	6.21
Beta (2Y)	1.76
Beta (5Y)	1.73
Change from 52-week high	-49.17%
Change from 52-week low	319.84%
Change from all-time high	-99.05%
Change from all-time low	324.92%
Change from open	-1.18%
Day's gap	1.53%
Dollar volume	$3.2M
High price	$30.77
Low price	$29.80
Monthly RSI	46.47
Open price	$30.53
Position in 52-week range	38.14%
Previous close	$30.07
Price vs 150-day SMA	18.39%
Price vs 20-day SMA	-4.83%
Price vs 200-day SMA	40.34%
Price vs 50-day SMA	-1.61%
Relative volume	0.78
RSI	46.7
Sharpe ratio	0.89
Sharpe ratio (3Y)	0.7
Sharpe ratio (5Y)	0.36
Sortino ratio	4.25
Sortino ratio (3Y)	2.49
Sortino ratio (5Y)	1.09
Volume	107.5K
Weekly RSI	59.89
YTD price change	243.48%
YTD total return	243.48%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	32.7M
Float percentage	71.9%
Shares change (QoQ)	150%
Shares held by insiders	0.31%
Shares held by institutions	15.71%
Shares outstanding	45.5M
Short % of float	0.04%
Short % of shares	0.03%
Short ratio	0.1 days

Deeper analysis on KRSA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this KRSA report

Is a complete KRSA research report available?

No complete published report is available for KRSA (KRSA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

KRSA (KRSA)

Price

Financial snapshot

Fair-value bridge

Latest news · KRSA

Valuation

Balance sheet

Trading

Next earnings

Sector percentile context

All KRSA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on KRSA

Frequently asked questions